Clinical Trials Browser

Completed × Has results × trastuzumab deruxtecan × Clear all

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast

Breast Neoplasms

NCT04744831 2026-01-14

DESTINY-CRC02

Phase 2 Completed

122 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04644237 2025-11-21

DESTINY-LUNG02

Phase 2 Completed

152 enrolled 22 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04420598 2025-06-24

DEBBRAH

Phase 2 Completed

41 enrolled 32 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2 Completed

79 enrolled 19 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Phase 1 Completed

86 enrolled 22 charts

BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04989816 2024-11-21

DG-06

Phase 2 Completed

95 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Phase 1 Completed

292 enrolled 35 charts 2 FDA

Tumor-Agnostic

Neoplasms

NCT03383692 2023-12-11

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Phase 1 Completed

40 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Completed

12 enrolled 15 charts

BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT03366428 2022-04-12

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Phase 1 Completed

51 enrolled 14 charts

Breast

Breast Neoplasms, Neoplasms

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2 Completed

233 enrolled 26 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

NCT03384940 2021-10-18

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Phase 2 Completed

86 enrolled 26 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

Clinical Trials

HER2CLIMB-04

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

DESTINY-CRC02

DESTINY-LUNG02

DEBBRAH

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

DG-06

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)